Ticker Details
Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
IPO Date:	February 4, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$364.13M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.90%
Avg Daily Range (30 D):	$0.43 | 7.94%
Avg Daily Range (90 D):	$0.23 | 5.14%

Institutional Daily Volume
Avg Daily Volume:	1.44M
Avg Daily Volume (30 D):	6.66M
Avg Daily Volume (90 D):	2.76M

Trade Size
Avg Trade Size (Sh.):	271
Avg Trade Size (Sh.) (30 D):	142
Avg Trade Size (Sh.) (90 D):	137

Institutional Trades
Total Institutional Trades:	1,292
Avg Institutional Trade:	$1.64M
Avg Institutional Trade (30 D):	$.77M
Avg Institutional Trade (90 D):	$1.15M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.75M
Avg Closing Trade (30 D):	$.84M
Avg Closing Trade (90 D):	$1.4M
Avg Closing Volume:	46.27K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 5, 2026 @ 11:04 PM Agenus (AGEN) Q3 2024 Earnings Call Transcript Source: Motley Fool Transcribing

Aug 28, 2025 @ 2:44 PM FDA Tightens Survival Standards as Cancer Drug Pip... Source: Prnewswire

Aug 18, 2025 @ 5:00 PM PD-(L)1 Inhibitors Market Set to Surge During the ... Source: Delveinsight

Aug 13, 2025 @ 2:00 PM U.S. Pharmaceutical CDMO Market Valuation to Surpa... Source: Towards Healthcare

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$2.6	$-.01	$1.03
Diluted EPS	$2.53	$-.01	$1.02
Revenue	$132.69M	$34.52M	$33.74M
Gross Profit
Net Income / Loss	$91.94M	$-.57M	$39.21M
Operating Income / Loss	$36.2M	$11.29M	$15.05M
Cost of Revenue	$.64M	$M	$M
Net Cash Flow	$7.32M	$-16.25M	$32.01M
PE Ratio

Splits
Apr 12, 2024	1:20
Oct 03, 2011	1:6